Latest From William Masters
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In an interview with Scrip, CEO Saurabh Saha elaborates on the first-of-its-kind R&D model.
Novadiscovery has received funding from Sanofi and will support the French major’s COVID-19 efforts with its virtual JINKO clinical trial platform.
A new joint venture from Avacta and Daewoong Pharmaceutical aims to use novel mesenchymal stem cells to secrete antibody mimetic "Affimers" to treat inflammatory diseases.
Plus deals involving Helixmith/Wacker, Sosei Heptares/Metrion, Ono/Ribon, Asahi Kasei/Lilly, Citrine/Diurnal, Mitsubishi Tanabe/Aquestive, Immunotech/T-Cure, TRIGR/Elpiscience, Daiichi Sankyo/ViGeneron
Lyon, France-based Novadiscovery is developing a user-facing technology to run in silico studies, a method it expects to cut development costs and improve trial success rates. But acceptance of “new” data types is often a concern for drug developers, despite world-leading regulatory bodies stating their desire for 21st century approaches.